Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Diffuse Parenchymal Lung Disease
- Sponsor
- Sheba Medical Center
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD.
- Last Updated
- 3 years ago
Overview
Brief Summary
The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims:
- Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping.
- Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.
Investigators
Dr. Liran Levy
Transplant pulmonologist
Sheba Medical Center
Eligibility Criteria
Inclusion Criteria
- •suspected or known DPLD
- •referred to DPLD observation
Exclusion Criteria
- •other lung related diseases
Outcomes
Primary Outcomes
The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD.
Time Frame: during the procedure/surgery
The diagnostic performance will be evaluated according to the biopsy results
The primary outcome measure of this study is to determine the prognostic performance of ULDCT in the follow up of DPLD.
Time Frame: during the procedure/surgery
The diagnostic performance will be evaluated according to the biopsy results